SAN DIEGO–(BUSINESS WIRE)–Launched on 9/15, San Diego’s Stratify Genomics, Inc. announced Prompt®,
a test to evaluate a man’s genetic predisposition to prostate cancer,
designed to provide knowledge of an individual’s baseline prostate
cancer risk, which is critical to an informed conversation regarding the
risks/benefits of prostate cancer screening.
Currently, there are 35,000 men annually who are unaware of a curable
form of clinically significant prostate cancer. Relying solely on family
history, 80% of prostate cancer cases would be missed. The most common
screening tool, prostate-specific antigen (PSA) testing, has declined in
usage due to controversial guidelines, which has led to a significant
increase in metastatic prostate cancer.
“We are in the midst of a healthcare crisis with the abandonment of
PSA-based prostate cancer screening,” says A. Karim Kader, MD, PhD,
Founder, Head of Urologic Oncology at University of California, San
Diego. “Men at high risk for the second most leading cause of
cancer-related deaths deserve to know about and act upon their baseline
Prompt® can take the guesswork out of the decision to have a PSA
screening. Rather than screening all men solely based on family history,
Prompt® offers a stable, objective measure, including family history, of
lifetime risk of prostate cancer. Clinicians can focus screening efforts
on men who are at greatest risk and better informs patients of their
individualized risk. This
test, performed with a cheek swab sample, at any age, can help men
know their individual risk and may identify high-risk men.
By focusing PSA screening on men at higher risk, the healthcare system
could realize billions of dollars in costs
savings annually, with tens of
thousands of men potentially saved from developing metastatic
With a scientific advisory board made up of prestigious names that
include Dr. Gerald Andriole, Dr. Christopher Kane, Dr. Karim Kader and
Dr. Franklin Gaylis, Prompt® is based on a decade of work and hundreds
of millions of dollars in research funding. It has been validated in
over 10,000 men and indirectly validated in over 100,000 men. The test
incorporates the genetic information from dozens of prostate cancer-risk
Stratify is currently working with nine major partners and urology
clinics across the country.
To learn more about Stratify Genomics and Prompt®, please visit http://www.stratifygenomics.com/
or call 888-571-8810.